Teva has announced a leadership change in its global operations, while Lupin has made a key appointment to focus on quality and compliance. Among other changes in leadership roles, Olainfarm has seen one of its six management board members resign.
Teva has announced the appointment of Eric Drapé as executive vice-president for global operations. Drapé, who joined Teva in 2014 and has served in various senior management positions – including his current role as chief quality officer and also as head of Teva’s biologics operations – will be based out of Teva’s global headquarters in Israel.
Drapé has taken over the role of vice-president of global operations following the retirement of Carlo de Notaristefani. Teva president...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
